For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Noopept vs Pinealon

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

NoopeptPinealon
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asGVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl EsterEDR, Glu-Asp-Arg, Pineal tripeptide
EvidenceResearch-stageResearch-stage
Dosing range5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles)100mcg–300mcg mcg, Once daily (evening, given melatonin/sleep effects)
AdministrationOral (capsule/powder), Sublingual (dissolved under tongue), IntranasalSubcutaneous injection, Intranasal, Oral (sublingual for better absorption)
Key side effectsHeadache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day)Generally well-tolerated, Drowsiness if dosed during the day, Vivid dreams (common — melatonin pathway activation), Mild headache (uncommon)
Cited sources2 references2 references

Key differences

  • Administration: Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal; Pinealon — Subcutaneous injection, Intranasal, Oral (sublingual for better absorption).
  • Dosing units differ: Noopept is dosed in mg, Pinealon in mcg — they operate at different scales.
  • Frequency: Noopept is typically 1–3x daily oral or sublingual (8–12 week cycles); Pinealon is Once daily (evening, given melatonin/sleep effects).

How each works

Noopept

Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.

Pinealon

Like other peptide bioregulators from the Khavinson group, Pinealon is proposed to work by penetrating the nuclear membrane and interacting directly with histones and promoter regions to regulate transcription. In vitro studies show Pinealon increases synthesis of serotonin and melatonin precursors in pinealocytes and upregulates antioxidant enzyme expression in neuronal cells. Animal studies demonstrate reduced neuronal apoptosis after hypoxic stress and improved performance in cognitive tasks. Clinical observations from Russian gerontology practice suggest benefits for insomnia, age-related cognitive decline, and neurological recovery.

Read the full Noopept profileRead the full Pinealon profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.